| Literature DB >> 24265586 |
L Jurcikova1, V Adamkova, V Lanska, P Suchanek, Ja Hubacek.
Abstract
The aim of this study was to examine single nucleotide polymorphisms (SNPs) of candidate genes α 2-Heremans-Schmid glycoprotein ( AHSG , rs4917), Hypocretin ( HCRT , rs760282) and Neuropetide Y2 receptor (NPY2R , rs 1047214), which are known to have a potential effect on body mass index (BMI) and other indicators of obesity. A population study was performed in 2007/2008 on 2559 adults (1191 males and 1368 females) from the Czech post-MONICA project. The SNPs were examined using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. We did not find any significant association between the examined SNPs and BMI across the whole population. A significantly lower triglyceride level was found in the AHSG gene CC homozygotes compared to T allele carriers in the entire population ( p = 0.009). In conclusion, we are not able to confirm the hypothesis that polymorphisms within the AHSG , HCRT and NPY2R genes are major genetic determinants of BMI and plasma lipids in the Czech-Slavonic population.Entities:
Keywords: Body mass index (BMI); Hypocretin ( HCRT ) gene; Neuropetide Y2 receptor ( NPYR ) gene; single nucleotide polymorphism (SNP); α 2-Heremans-Schmid glycoprotein ( AHSG ) gene
Year: 2013 PMID: 24265586 PMCID: PMC3835298 DOI: 10.2478/bjmg-2013-0019
Source DB: PubMed Journal: Balkan J Med Genet ISSN: 1311-0160 Impact factor: 0.519
Basic characteristics of the analyzed individuals (values are expressed as mean ± SD).
|
|
| |
|---|---|---|
| Number of subjects | 1191 | 1368 |
| Age (years) | 49.00 ± 10.80 | 48.60 ± 10.60 |
| Total cholesterol (mmol/L) | 5.76 ± 1.06 | 5.80 ± 1.15 |
| Triglycerides (mmol/L) | 1.97 ± 1.28 | 1.47 ± 0.82 |
| Body mass index (kg/m 2 ) | 28.20 ± 4.00 | 27.60 ± 5.50 |
| Non smokers (%) | 67.30 | 78.50 |
| Diabetes prevalence (%) | 8.90 | 6.80 |
| Hypertension prevalence (%) | 40.70 | 33.10 |
Primers sequence, restriction enzymes and size of the restriction fragments used for detection of polymorphisms in genes for AHSG, prepro-orexine and NPY2R.
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|
|
| ||||||
|
| F: TGG GGC AGA GGT TGC AGT GAC CTC C | 132 bp |
| 132 | C | Thr |
| rs4917 | R: AAT GTC CTG TCA TCA CTA CTG CAC TGC | 105 + 27 | T | Met | ||
|
| ||||||
|
| F: ATA AGA AGC TTG GGC CTG GA | 1575 bp | ||||
| rs760282 | R: ACC TTG AAA ACT CAG CCT AGA CAG T | |||||
| – Nested PCR |
F: GCG GGG GGG
| 295 bp |
| 295 | C | |
| R: ACT AAA TTT TGG TCT TGT TGC TCA G | 108 + 187 | T | Regulatory region | |||
|
| ||||||
|
| F: ATC AGC TTC CTG ATT ATT GGC TTG GC | 174 bp |
| 174 | C | Ile |
| rs1047214 | R: AAG ACT ATA GAC AGT GCC ATA GAT GC | 95 + 79 | T | Ile | ||
Genotypes and frequencies of examined SNPs in the Czech post-MONICA study.
|
|
| |||
|---|---|---|---|---|
| Genes |
|
|
|
|
|
| 199 (9.4) | 959 (45.1) | 969 (45.6) | 83.1 |
|
Males |
91 (9.5) |
424 (44.4) |
441 (46.1) | |
|
| 1062 (53.4) | 795 (40.0) | 132 (6.6) | 77.7 |
|
Males |
454 (51.9) |
349 (39.9) |
71 (8.1) | |
|
| 716 (32.9) | 1058 (49.4) | 366 (17.7) | 98.4 |
|
Males |
331 (34.4) |
472 (49.0) |
160 (16.6) | |
Impact of genotype and gender on anthropometrical parameters. [The asterisk (*) denotes statistical significance.]
|
|
|
| ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||
|
|
|
|
|
|
|
|
|
|
| |
|
| ||||||||||
| Body mass index (kg/m 2 ) | M | 28.85±4.12 | 28.90±4.04 | 28.75±4.09 | 29.00±4.34 | 28.85±4.10 | 28.82±3.98 | 29.19±4.43 | 28.93±4.12 | 28.62±3.82 |
| F | 28.07±5.45 | 28.49±5.53 | 28.19±5.78 | 28.69±6.54 | 18.15±5.28 | 28.40±5.53 | 28.53±5.73 | 28.25±5.33 | 28.17±5.67 | |
|
| ||||||||||
|
|
|
|
| |||||||
|
| ||||||||||
| Waist-hip ratio | M | 0.94±0.07 | 0.94±0.06 | 0.95±0.06 | 0.95±0.06 | 0.94±0.07 | 0.94±0.06 | 0.94±0.06 | 0.94±0.06 | 0.94±0.07 |
| F | 0.83±0.07 | 0.84±0.07 | 0.82±0.08 | 0.83±0.06 | 0.83±0.07 | 0.83±0.07 | 0.84±0.07 | 0.84±0.07 | 0.84±0.07 | |
|
| ||||||||||
|
|
|
|
| |||||||
|
| ||||||||||
| Cholesterol (mmol/L) | M | 5.24±0.99# | 5.36±1.07 | 5.21±0.88 | 5.59±0.90 | 5.30±1.04 | 5.27±1.01 | 5.33±0.99 | 5.27±1.02 | 5.30±1.01 |
| F | 5.40±1.02 | 5.44±1.03 | 5.26±1.03 | 5.45±0.97 | 5.44±1.03 | 5.38±1.08 | 5.41±1.00 | 5.42±1.04 | 5.33±1.10 | |
|
| ||||||||||
|
|
|
|
| |||||||
|
| ||||||||||
| High density lipoproteins (mmol/L) | M | 1.29±0.30 | 1.31±0.34 | 1.24±0.30 | 1.32±0.34 | 1.30±0.33 | 1.29±0.29 | 1.33±0.33 | 1.29±0.32 | 1.28±0.31 |
| F | 1.59±0.39 | 1.56±0.358 | 1.55±0.36 | 1.59±0.39 | 1.57±0.36 | 1.58±0.38 | 1.54±0.37 | 1.58±0.39 | 1.58±0.36 | |
|
| ||||||||||
|
|
|
|
| |||||||
|
| ||||||||||
| Low density lipoproteins (mmol/L) | M | 3.20±0.88 | 3.23±0.92 | 3.15±0.78 | 3.51±0.82 | 3.19±0.89 | 3.22±0.91 | 3.24±0.93 | 3.19±0.89 | 3.23±0.87 |
| F | 3.20±0.97 | 3.26±0.97 | 3.05±0.89 | 3.24±0.89 | 3.24±0.97 | 3.19±0.96 | 3.23±0.94 | 3.22±0.99 | 3.19±0.94 | |
|
| ||||||||||
|
|
|
|
| |||||||
|
| ||||||||||
| Triglycerides (mmol/L) | M | 1.68±1.08 | 1.86±1.37 | 1.92±1.42 | 1.78±1.34 | 1.81±1.17 | 1.76±1.32 | 1.74±1.14 | 1.76±1.18 | 1.84±1.39 |
| F | 1.33±0.73 | 1.38±0.84 | 1.39±1.57 | 1.30±0.53 | 1.40±0.94 | 1.34±0.89 | 1.39±0.68 | 1.37±0.87 | 1.33±1.00 | |
|
| ||||||||||
|
|
|
|
| |||||||
|
| ||||||||||
| Glycemia (mmol/L) | M | 5.91±1.59 | 5.76±1.18 | 5.77±1.43 | 5.67±0.97 | 5.88±1.47 | 5.81±1.42 | 5.83±1.48 | 5.85±1.37 | 5.82±1.43 |
| F | 5.51±1.39 | 5.47±1.17 | 5.41±1.00 | 5.59±1.23 | 5.53±1.56 | 5.46±1.07 | 5.52±1.32 | 5.50±1.19 | 5.47±1.40 | |
|
| ||||||||||
|
|
|
|
| |||||||